News Sentiment

LRMR sentiment intelligence

Larimar Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.28 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+31.3% over one week, +23.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 31.3% Price confirming higher
Trend fit Trend inactive 23.3% over four weeks
Fair value -12.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 36
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 10
TradingView 8
simplywall.st 5
GlobeNewswire 4
Stocktwits 3
Moomoo 2
StocksToTrade 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 13
Regulatory and legal 8
Analyst action 5
Deals and strategy 3
Balance sheet 2
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
StocksToTrade Direct company coverage

LRMR Stock Slides As Traders Eye Cash Runway And Volatility

Larimar Therapeutics Inc. (LRMR) stock has dropped by 14.62% due to bearish sentiment surrounding its recent clinical developments. Despite concerns over profitability, the company maintains a strong cash position of approximately $178 million, providing a significant runway for

Tone
Negative 39/100
Event
Balance sheet
Published
29 Jun 2026 10:03
Source
StocksToTrade
marketscreener.com Direct company coverage

Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 2000 Growth Benchmark

Larimar Therapeutics, Inc. (NasdaqGM: LRMR) has been added to the Russell 2000 Growth Benchmark index. This inclusion highlights the company's growth trajectory within the biotechnology and medical research sector. The company is focused on developing treatments for rare diseases

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 07:01
Source
marketscreener.com
Moomoo Direct company coverage

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia

Larimar Therapeutics is hosting an investor event to discuss updates on its nomlabofusp program for Friedreich's Ataxia. This event will provide insights into the progress and future plans for this therapeutic candidate. Investors will have the opportunity to learn more about the

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 02:10
Source
Moomoo
Investing.com Australia Direct company coverage

Larimar Therapeutics to host investor event on Monday By Investing.com

Larimar Therapeutics (NASDAQ:LRMR) is hosting an investor event on Monday, June 29, 2026, to discuss updates on its nomlabofusp clinical development program for Friedreich's ataxia, including regulatory information and long-term study data. The clinical-stage biotech company, wit

Tone
Positive 66/100
Event
Regulatory and legal
Published
27 Jun 2026 01:39
Source
Investing.com Australia